clover health (nasdaq: clov) is a physician enablement company focused on seniors who have historically lacked access to affordable, high-quality healthcarewe aim to provide great care, in a sustainable way, by having a business model built around improving medical outcomes while lowering avoidable costs. we do this while taking a holistic approach to understanding the health needs and social risk factors of those under our care. this strategy is underpinned by our proprietary software platform, the clover assistant, which is designed to aggregate patient data from across the health ecosystem to support clinical decision-making by presenting physicians and other providers with real-time, personalized recommendations at the point of care.making care more accessible is at the heart of our business, and we believe patients should have the freedom to choose their doctors. we offer affordable medicare advantage plans with extensive benefits, provide primary care physicians with the clover a
Company profile
Ticker
CLOV
Exchange
Website
CEO
Vivek Garipalli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Social Capital Hedosophia Holdings Corp. III
SEC CIK
Corporate docs
Subsidiaries
Clover Health Labs, LLC • Clover Health Holdings, Inc. • Clover Health Partners, LLC • Clover Health, LLC • Clover HMO of New Jersey Inc. • Clover Insurance Company • Medical Service Professionals of NJ LLC • Juxly, LLC ...
IRS number
981515192
CLOV stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
29 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Clover Health Reports Strong First Quarter 2024 Financial Results; Improves Guidance to Target Full-Year 2024 Adjusted EBITDA Profitability
7 May 24
ARS
2024 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
22 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Apr 24
8-K
Other Events
4 Apr 24
S-8
Registration of securities for employees
28 Mar 24
Transcripts
CLOV
Earnings call transcript
2024 Q1
7 May 24
CLOV
Earnings call transcript
2023 Q4
12 Mar 24
CLOV
Earnings call transcript
2023 Q3
6 Nov 23
CLOV
Earnings call transcript
2023 Q2
9 Aug 23
CLOV
Earnings call transcript
2023 Q2
8 Aug 23
CLOV
Earnings call transcript
2023 Q1
9 May 23
CLOV
Earnings call transcript
2022 Q4
28 Feb 23
CLOV
Earnings call transcript
2022 Q3
7 Nov 22
CLOV
Earnings call transcript
2022 Q2
9 Aug 22
CLOV
Earnings call transcript
2022 Q1
10 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 208.26 mm | 208.26 mm | 208.26 mm | 208.26 mm | 208.26 mm | 208.26 mm |
Cash burn (monthly) | (no burn) | 5.42 mm | 7.57 mm | 13.22 mm | (no burn) | 14.08 mm |
Cash used (since last report) | n/a | 12.50 mm | 17.45 mm | 30.49 mm | n/a | 32.47 mm |
Cash remaining | n/a | 195.76 mm | 190.80 mm | 177.77 mm | n/a | 175.78 mm |
Runway (months of cash) | n/a | 36.1 | 25.2 | 13.4 | n/a | 12.5 |
Institutional ownership, Q2 2022
1.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 5.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Integrated Core Strategies | 5.40 mm | $0.00 |
Linden Capital | 100.47 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 May 24 | Anna U Loengard | Class A Common Stock | Buy | Acquire P | Yes | No | 0.93 | 10,000 | 9.30 k | 10,000 |
16 May 24 | Anna U Loengard | Class A Common Stock | Buy | Acquire P | Yes | No | 0.94 | 1,485 | 1.40 k | 15,110 |
16 May 24 | Anna U Loengard | Class A Common Stock | Buy | Acquire P | Yes | No | 0.96 | 15,600 | 14.98 k | 15,600 |
14 May 24 | Karen Soares | Class A Common Stock | Payment of exercise | Dispose F | No | No | 1.02 | 5,241 | 5.35 k | 979,760 |
9 May 24 | Aric R Sharp | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.86 | 6,798 | 5.85 k | 1,788,476 |
8 May 24 | Andrew Toy | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.87 | 85,367 | 74.27 k | 10,504,370 |
News
Peering Into Clover Health Investments's Recent Short Interest
7 Jun 24
Clover Health Appoints Peter Kuipers As Chief Financial Officer, Effective As Of The Day After The Filing Of The Co's Quarterly Report On Form 10-Q For The Quarter-Ended March 31, 2024
22 Apr 24
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
26 Mar 24
Peering Into Clover Health Investments's Recent Short Interest
15 Mar 24
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
13 Mar 24
Press releases
Clover Health to Report First Quarter 2024 Financial Results on May 7, 2024
23 Apr 24
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
22 Apr 24
Clover Health Provides Notice Associated with Previously Disclosed Settlement of Shareholder Derivative Actions
4 Apr 24
Clover Health's Remarkable Turnaround: A Deep Dive into 2023 Results and 2024 Outlook
13 Mar 24
Clover Health Reports Fourth Quarter and Full Year 2023 Financial Results; Delivers Continued Momentum in Financial Performance and Provides Full-Year 2024 Guidance
12 Mar 24